Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.

Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.

View in: PubMed